Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ACB vs MTLS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MTLS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

MTLS Overall Winner 6-Pillar Tally: ACB 2 – 4 MTLS Matrix Metrics: ACB 3 – 7 MTLS

As of Nov 17, 2026, Materialise NV (MTLS) is the stronger overall head-to-head candidate over Aurora Cannabis Inc. Common Shares (ACB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACB carries a Unified Composite Score of 40.1/100 (SELL) at $4.52 (109.9x Forward P/E, -13.8% operating margin), whereas MTLS carries 53.5/100 (HOLD) at $6.28 (N/M Forward P/E, 3.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACB vs MTLS
ACB NASDAQ
Aurora Cannabis Inc. Common Shares
Medicinal Chemicals & Botanical Products
$4.52
-1.95% 1D
Market Cap $324.8M
TTM Revenue $314M
Forward P/E 109.9x
Beta / 30D Vol 1.08β · 86% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 15.0 Fund 40.0 Flow 61.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 49.2 · SMA20: $4.58 · SMA50: $4.28
MTLS NASDAQ Head-to-Head Winner
Materialise NV
Services-Prepackaged Software
$6.28
+1.13% 1D
Market Cap $369.9M
TTM Revenue $605M
Forward P/E N/M
Beta / 30D Vol 1.10β · 88% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 53.0 Fund 53.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 31
RSI-14: 31.4 · SMA20: $7.28 · SMA50: $7.78

6-Pillar Scorecard Institutional Category Breakdown (ACB 2 – 4 MTLS)

Columns: Metric · ACB · MTLS
1. Valuation Multiples MTLS
Forward P/E 109.9x N/M
Trailing P/E 109.9x 25.0x
PEG Ratio N/M 1.26x
EV / Revenue 0.9x 0.6x
2. Growth & Scale MTLS
Revenue Growth (YoY) -8.8% +2.1%
Earnings Growth (YoY) -94.7% -33.3%
TTM Revenue (USD) $314M $605M
Market Cap $324.8M $369.9M
3. Profitability & Quality MTLS
Gross Margin 44.2% 57.4%
Operating Margin -13.8% 3.4%
Net Profit Margin -38.2% 4.6%
Return on Equity (ROE) -9.4% 5.0%
4. Balance Sheet & Cash Flow MTLS
Cash Generation (TTM) -$25M $55M EBITDA
Cash Flow Margin -8.1% 9.1% EBITDA Mgn
Net Cash / Leverage $44M Net Cash $4.97 Book/Sh · 5.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACB
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 30.6% (6th %ile) N/A (N/A)
Put/Call OI Skew 0.23x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ACB
OpEx & R&D Intensity 58.0% of Rev ($182M) 54.0% of Rev ($327M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Software - Application Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACB (3) vs MTLS (7)
Institutional Metric ACB MTLS Criterion Row Edge
Market Capitalization
Scale
$324.8M $369.9M Larger Scale MTLS
Trailing P/E Ratio
Valuation
109.9x 25.0x Lower Multiple MTLS
Forward P/E Ratio
Valuation
109.9x N/M Lower Multiple ACB
Revenue Growth (YoY)
Growth
-8.8% +2.1% Higher Growth MTLS
Operating Margin (TTM)
Profitability
-13.8% 3.4% Higher Margin MTLS
Net Profit Margin
Profitability
-38.2% 4.6% Higher Margin MTLS
Return on Equity (ROE)
Capital Efficiency
-9.4% 5.0% Higher ROE MTLS
52-Week Range Position
Momentum
52% ($3–$6) 37% ($5–$9) Stronger Trend ACB
Beta / 30D Volatility
Risk Regime
1.08β · 86% Vol 1.10β · 88% Vol Lower Realized Risk ACB
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 53.5 / 100 (HOLD) Higher Composite MTLS
Trailing 12M Revenue (USD)
Operating Scale
$314M $605M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.2% 57.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev 1.26x PEG · 0.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$25M ($44M Net Cash) $55M EBITDA ($4.97 Book/Sh · 5.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACB +36.66 pp
ACB: +14.14% · MTLS: -22.52%
3M Horizon ACB +20.01 pp
ACB: +15.6% · MTLS: -4.41%
6M Horizon ACB +24.02 pp
ACB: +36.97% · MTLS: +12.95%
1Y Horizon ACB +0.38 pp
ACB: +4.87% · MTLS: +4.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACB vs MTLS. Trailing 12-month operating profitability (ACB -13.8% vs MTLS 3.4%) and valuation multiples (ACB 109.9x vs MTLS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ACB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$314M
Gross Margin44.2%
Op. Margin-13.8%
ROE / Fwd P/E-9.4% · 109.9x
MTLS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$605M
Gross Margin57.4%
Op. Margin3.4%
ROE / Fwd P/E5.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACB CONSOLIDATION
30d in phase · OBV DISTRIBUTION
Current IV 30.6%
IV Percentile 6th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MTLS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACB Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $324.8M market capitalization and -13.8% operating margin.
OpEx & R&D Reinvestment 58.0% of Rev ($182M)
90D Engineering Disclosures 0 Published
MTLS Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $369.9M market capitalization and 3.4% operating margin.
OpEx & R&D Reinvestment 54.0% of Rev ($327M)
90D Engineering Disclosures 0 Published

Investor FAQ ACB vs MTLS Key Questions & Quantitative Answers

As of Nov 17, 2026, Materialise NV (MTLS) is the stronger overall head-to-head candidate over Aurora Cannabis Inc. Common Shares (ACB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACB carries a Unified Composite Score of 40.1/100 (SELL) at $4.52 (109.9x Forward P/E, -13.8% operating margin), whereas MTLS carries 53.5/100 (HOLD) at $6.28 (N/M Forward P/E, 3.4% operating margin). Technically, ACB sits in a Neutral phase (RSI 49.2, CONSOLIDATION options structure) and MTLS sits in a Neutral phase (RSI 31.4, UNCLASSIFIED options structure).

MTLS leads the Growth & Scale pillar: ACB posts -8.8% YoY revenue growth and -94.7% YoY earnings growth on $314M TTM revenue (44.2% gross margin, -13.8% operating margin), compared with MTLS at +2.1% YoY revenue growth and -33.3% YoY earnings growth on $605M TTM revenue (57.4% gross margin, 3.4% operating margin). On trailing 12-month operating scale, ACB generates $314M in USD-normalized revenue versus $605M for MTLS. In operating R&D and SG&A reinvestment, ACB deploys 58.0% of Rev ($182M) (0 90-day corporate R&D disclosures) versus 54.0% of Rev ($327M) (0 disclosures) for MTLS.

MTLS screens cheaper on headline valuation multiples. ACB trades at 109.9x Forward P/E, 109.9x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-8.1% FCF margin), whereas MTLS trades at N/M Forward P/E, 25.0x Trailing P/E, 1.26x PEG, and 0.6x EV/Revenue (9.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACB (-9.4% ROE) versus MTLS (5.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ACB carries 30.6% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.08β · 86% Vol realized risk). By comparison, MTLS carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.10β · 88% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.